Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7501 to 7515 of 8314 results

  1. Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]

    Discontinued Reference number: GID-TA10401

    Technology appraisal guidance
    Discontinued

  2. PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

    Discontinued Reference number: GID-TA10402

    Technology appraisal guidance
    Discontinued

  3. Avelumab for previously treated platinum-resistant ovarian cancer ID1497

    In development Reference number: GID-TA10404 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

    In development Reference number: GID-TA10405 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued Reference number: GID-TA10413

    Technology appraisal guidance
    Discontinued

  6. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

    Technology appraisal guidance
    Discontinued

  8. Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

    Discontinued Reference number: GID-TA10422

    Technology appraisal guidance
    Discontinued

  9. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

    Technology appraisal guidance
    Discontinued

  10. Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

    Discontinued Reference number: GID-TA10427

    Technology appraisal guidance
    Discontinued

  11. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

    Technology appraisal guidance
    Discontinued

  12. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued Reference number: GID-TA10437

    Technology appraisal guidance
    Discontinued

  13. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development Reference number: GID-TA11400 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development